Compare INNV & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | PGEN |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2021 | 2013 |
| Metric | INNV | PGEN |
|---|---|---|
| Price | $8.19 | $4.16 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $8.33 |
| AVG Volume (30 Days) | 280.3K | ★ 5.4M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $853,699,000.00 | $230,981,000.00 |
| Revenue This Year | $12.85 | $1,115.92 |
| Revenue Next Year | $8.88 | $81.04 |
| P/E Ratio | $60.64 | ★ N/A |
| Revenue Growth | ★ 11.76 | N/A |
| 52 Week Low | $2.60 | $1.23 |
| 52 Week High | $10.69 | $5.47 |
| Indicator | INNV | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 56.98 |
| Support Level | $7.57 | $4.02 |
| Resistance Level | $9.18 | $4.44 |
| Average True Range (ATR) | 0.35 | 0.33 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 65.55 | 82.71 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.